Tenaya Therapeutics Reports Q1 Results, Announces Alnylam Collaboration Amidst Nasdaq Delisting Risk
TNYA has more than doubled off its 52-week low of $0.36.
Summary
Tenaya Therapeutics reported a reduced net loss in Q1 2026 and announced a significant collaboration with Alnylam Pharmaceuticals, but faces a Nasdaq delisting risk and high potential share dilution.
Key Events · Earnings and Guidance · TNYA
-
Q1 2026 Financial Performance
The company reported a net loss of $19.3 million for Q1 2026, a 28% improvement from the $26.9 million net loss in Q1 2025, driven by a 30% reduction in R&D expenses and a 16% reduction in G&A expenses.
-
New Collaboration with Alnylam Pharmaceuticals
In March 2026, Tenaya entered a multi-target research collaboration with Alnylam Pharmaceuticals to discover novel gene targets for cardiovascular disease. The agreement includes an upfront platform access fee of $10 million and potential development and commercial milestone payments of up to $1.1 billion.
-
Liquidity and Cash Runway
As of March 31, 2026, Tenaya had $80.9 million in cash and cash equivalents. Management believes existing cash will fund operations for at least the next twelve months from the filing date (into Q2 2027).
-
Nasdaq Delisting Notice
On January 28, 2026, the company received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price rule, with 180 calendar days to regain compliance.
Analysis · TNYA · Life Sciences
Tenaya Therapeutics' Q1 2026 results show a reduced net loss, primarily due to decreased operating expenses. The new collaboration with Alnylam Pharmaceuticals is a significant strategic development, offering substantial potential milestone payments and research funding, which could provide a long-term financial boost. However, the company faces immediate and critical challenges, including a Nasdaq delisting notice due to its stock price falling below $1.00, and a substantial overhang from potentially dilutive securities. The stated cash runway of at least 12 months is crucial for a clinical-stage biotech, highlighting the ongoing need for careful financial management and potential future capital raises.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNYA was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.5M. The 52-week trading range was $0.36 to $2.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.